On Jun. 3, 2022, BD announced it will introduce new cell sorting technology at the International Society for Advancement of Cytometry (ISAC) CYTO 2022 conference June 3-7 that enables researchers to see and sort cells at speeds never before possible, which creates the potential to transform research and cell-based therapeutic development across a range of fields such as virology and oncology, as well as numerous disease states.

The new BD FACSDiscover™ S8 Cell Sorter features the breakthrough BD CellView™ Image Technology profiled earlier this year on the cover of the journal Science. It is the first cell sorter to combine advanced spectral flow cytometry with sort-capable image analysis that will potentially enable researchers to yield more accurate data and sort cells that previously could not be identified.

Cell sorting through spectral flow cytometry is a cutting-edge technique that captures the full spectrum signal emitted by sample preparations instead of specific bands as with traditional flow cytometry, letting scientists sort cells using more parameters to better understand human health, disease and treatment.

The BD FACSDiscover™ S8 Cell Sorter combines advanced spectral flow cytometry with the novel BD CellView™ Image Technology, which captures images of individual cells flowing through the system and sorts them based on detailed microscopic image analysis of each one at high sort speeds. This combination enables scientists to gain more accurate insights on cell populations and characteristics that can be visually confirmed in real time, and interrogate and sort cells that could not be identified before, all in a simplified experimental workflow. The BD FACSDiscover™ S8 Cell Sorter is the first BD instrument to feature BD CellView™ Image Technology.

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues.